LONDON–(BUSINESS WIRE)–#DrugPipeline–Technavio has published a new report on the drug development pipeline for cataract therapeutics, including a detailed study of the pipeline molecules.
Category: Business
EyeQue Hires Chief Marketing Officer to Strengthen Leadership Team for Accelerated Company Growth
NEWARK, Calif.–(BUSINESS WIRE)–#seebeyond–EyeQue adds industry veteran Datta Nadkarni as CMO to lead next revolution of eye care– at-home vision testing.
Aerpio Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Tuesday, August 14, 2018
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that its second quarter 2018 financial results will be released before the market opens on Tuesday, August 14, 2018. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live
Company Profile for RadianceTx
–(BUSINESS WIRE)–RadianceTx is a trademark of Radiance Therapeutics, Inc., a Delaware corporation. Radiance Therapeutics, Inc., a leader in ophthalmic therapeutic innovation, is commercializing a clinically demonstrated novel anti-metabolite therapy for glaucoma drainage surgery. For more information, visit: www.radiancetherapeutics.com. Company: RadianceTx Headquarters Address: 7440 N. Oracle Road, Bldg. 1 Tucson, AZ 85704 Main Telephone: Info@RadianceTx.com Website: http://www.radia
Omeros Corporation to Announce Second Quarter 2018 Financial Results on August 9, 2018
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its second quarter 2018 financial results for the period ended June 30, 2018, on Thursday, August 9, 2018, after the market closes. Omeros managemen…
Glaukos Corporation Announces Second Quarter 2018 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies desig…
Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institute, Inc.
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies desig…
BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the second quarter ended June 30, 2018 and recent corporate accomplishments. “BioTime’s execution in the second quarter demonstrates the strength of our strategy. Our focus on clinical progress has accelerated our product development of our core programs. With our non-core programs, we have, in fewer than two years, g
Global Ocular Implants Market Analysis, Trends & Forecasts 2018-2022, With an Expected CAGR of 12.52% – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Ocular Implants Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering. The analysts forecast the global ocular implants market to grow at a CAGR of 12.52% during the period 2018-2022. Ocular i…
Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Global Keratometers Market 2018-2022| Growth Potential in Emerging Economies to Propel Demand| Technavio
LONDON–(BUSINESS WIRE)–#Healthcare–The global keratometers market 2018-2022 is expected to post a CAGR of close to 4% during the forecast period, according to Technavio.
Global Fundus Cameras Market Analysis, Trends & Forecasts 2018-2022, With an Expected CAGR of Over 5% – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Fundus Cameras Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering. The analysts forecast the Global Fundus Cameras Market 2018-2022 to grow at a CAGR of 5.01% during the period 2018-2022. A…
Illuma Names Healthcare and Business Veterans to Board, Aims to Link Thousands More At-Risk Diabetics with Proper Eye Care
ATLANTA–(BUSINESS WIRE)–In a year of major growth and milestones in its unique and innovative mission to prevent blindness for millions of at-risk diabetic patients nationwide, Illuma Care Connections has named a leading health plan executive and a v…
Aerie Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 8, 2018
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its second quarter 2018 financial results will be released after the market closes on Wednesday, August 8, 2018. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company’s website
Ophthotech Reports Second Quarter 2018 Financial and Operating Results
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation today announced financial and operating results for the second quarter ended June 30, 2018 and provided a business update.
Aerie Pharmaceuticals, Inc. and DSM Biomedical, Inc. Expand Collaboration Agreement Focused on Novel Drug Delivery Technology in Ophthalmology
DURHAM, NC & EXTON, Pa.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, and DSM Biomedical, Inc., a global solutions provider in biomedical science and regenerative medicine, today reported that they have expanded their collaborative research, development, a
Ocular Therapeutix™ To Report Second Quarter 2018 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter ended June 30, 2018 financial results on Tuesday, August 7, 2018. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at
Thomas W. Burns, CEO of Glaukos, Joins Avedro’s Board of Directors
WALTHAM, Mass.–(BUSINESS WIRE)–#avedro–Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that Thomas W. Burns has been elected to its Board of Directors. Mr. Burns has a…
Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease
WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that the first patient has been dosed in STRIDE 3 (Short Term Relief In Dry Eye), its Phase 3 trial of KPI-121 0.25% for the short-term treatment of dry eye disease. “We are pleased to initiate the STRIDE 3 trial of KPI-121 0.25%. If approved, KPI-
Glaucoma Research Foundation Grant Leads to Major Breakthrough in Neuron Regeneration
SAN FRANCISCO–(BUSINESS WIRE)–#EyeCare–Research funded by the Glaucoma Research Foundation indicates use of insulin may lead to vision restoration in glaucoma patients.